Total Payments
$27,133
2024 Payments
$14,502
Companies
15
Transactions
47
Medicare Patients
637
Medicare Billing
$86,829
Payment Breakdown by Category
Consulting$15,088 (55.6%)
Other$4,999 (18.4%)
Travel$3,821 (14.1%)
Food & Beverage$1,944 (7.2%)
Research$1,270 (4.7%)
Education$11.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,088 | 6 | 55.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,999 | 1 | 18.4% |
| Travel and Lodging | $3,821 | 9 | 14.1% |
| Food and Beverage | $1,944 | 28 | 7.2% |
| Unspecified | $1,270 | 2 | 4.7% |
| Education | $11.50 | 1 | 0.0% |
Payments by Type
General
$25,863
45 transactions
Research
$1,270
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADC Therapeutics America, Inc. | $11,674 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $4,999 | 1 | $0 (2023) |
| Seagen Inc. | $4,888 | 6 | $0 (2023) |
| ABBVIE INC. | $1,742 | 6 | $0 (2024) |
| PFIZER INC. | $1,474 | 4 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $1,363 | 1 | $0 (2023) |
| Genentech, Inc. | $315.33 | 5 | $0 (2024) |
| Genmab U.S., Inc. | $310.89 | 4 | $0 (2024) |
| TG THERAPEUTICS, INC. | $105.94 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $87.05 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,502 | 20 | ADC Therapeutics America, Inc. ($11,674) |
| 2023 | $7,574 | 13 | Merck Sharp & Dohme LLC ($4,999) |
| 2022 | $4,586 | 5 | Seagen Inc. ($4,569) |
| 2021 | $316.69 | 4 | Genentech, Inc. ($177.45) |
| 2019 | $79.10 | 1 | Genentech USA, Inc. ($79.10) |
| 2017 | $76.06 | 4 | Allergan Inc. ($54.45) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 2 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2023 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,362.50 | General |
| Category: Oncology | ||||||
| 10/02/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $31.81 | General |
| 10/02/2023 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | Cash or cash equivalent | $12.72 | General |
| 08/02/2023 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 07/28/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $31.81 | General |
| 06/16/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $172.00 | General |
| 06/14/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $50.18 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2022 | Seagen Inc. | ADCETRIS (Biological) | Consulting Fee | Cash or cash equivalent | $2,475.00 | General |
| Category: Oncology | ||||||
| 10/07/2022 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $1,396.00 | General |
| Category: Oncology | ||||||
| 09/24/2022 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $370.35 | General |
| Category: Oncology | ||||||
| 09/01/2022 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $327.60 | General |
| Category: Oncology | ||||||
| 08/30/2022 | Collegium Pharmaceutical, Inc. | ELYXYB - celecoxib (Drug) | Food and Beverage | Cash or cash equivalent | $16.89 | General |
| Category: Migraine | ||||||
| 12/13/2021 | TG THERAPEUTICS, INC. | UKONIQ (Drug) | Food and Beverage | In-kind items and services | $105.94 | General |
| Category: Hematology | ||||||
| 12/10/2021 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $177.45 | General |
| 05/26/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: NEUROSCIENCE | ||||||
| 02/19/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2019 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $79.10 | General |
| 12/10/2017 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $21.61 | General |
| 04/03/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: NEUROSCIENCE | ||||||
| 03/22/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: NEUROSCIENCE | ||||||
| 01/18/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ADCETRIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 194 | 346 | $90,565 | $28,125 |
| 2022 | 4 | 146 | 222 | $54,195 | $19,007 |
| 2021 | 4 | 146 | 230 | $54,553 | $20,522 |
| 2020 | 7 | 151 | 259 | $73,083 | $19,175 |
Total Patients
637
Total Services
1,057
Medicare Billing
$86,829
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 118 | $30,279 | $9,325 | 30.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 43 | $12,728 | $4,379 | 34.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $14,057 | $3,964 | 28.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 72 | $12,434 | $3,675 | 29.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 49 | $10,094 | $3,318 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 23 | $8,061 | $2,487 | 30.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 14 | $2,912 | $977.76 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 120 | $26,351 | $9,458 | 35.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $14,034 | $4,315 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 51 | $7,279 | $2,685 | 36.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 21 | $6,531 | $2,549 | 39.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 64 | 133 | $28,475 | $10,978 | 38.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 28 | 32 | $9,677 | $3,946 | 40.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 23 | 23 | $10,555 | $3,434 | 32.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 31 | 42 | $5,846 | $2,164 | 37.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 40 | 93 | $26,500 | $5,851 | 22.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 25 | 25 | $15,428 | $3,518 | 22.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 31 | $7,786 | $2,839 | 36.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 36 | 60 | $10,629 | $2,402 | 22.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $5,923 | $2,133 | 36.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 23 | $4,124 | $1,461 | 35.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 15 | 15 | $2,693 | $970.05 | 36.0% |
About Dr. Ryan Lynch, MD
Dr. Ryan Lynch, MD is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2010. The National Provider Identifier (NPI) number assigned to this provider is 1386965952.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Lynch, MD has received a total of $27,133 in payments from pharmaceutical and medical device companies, with $14,502 received in 2024. These payments were reported across 47 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($15,088).
As a Medicare-enrolled provider, Lynch has provided services to 637 Medicare beneficiaries, totaling 1,057 services with total Medicare billing of $86,829. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Seattle, WA
- Active Since 06/17/2010
- Last Updated 07/21/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1386965952
Products in Payments
- ADCETRIS (Biological) $6,043
- IMBRUVICA (Drug) $1,363
- Epkinly (Drug) $310.89
- Lunsumio (Biological) $116.27
- UKONIQ (Drug) $105.94
- VENCLEXTA (Drug) $70.11
- NAMZARIC (Drug) $54.45
- UBRELVY (Drug) $21.80
- ELYXYB - celecoxib (Drug) $16.89
- TAZVERIK (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Seattle
Mr. John Pesando, Md, MD
Hematology & Oncology — Payments: $12.8M
Hematology & Oncology $12.8M
John Pagel, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Langdon Miller, Md, MD
Hematology & Oncology — Payments: $674,815
Hematology & Oncology $674,815
Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD
Hematology & Oncology — Payments: $534,649
Hematology & Oncology $534,649
Barbara Konkle, Md, MD
Hematology & Oncology — Payments: $331,390
Hematology & Oncology $331,390
Dr. Jill Johnsen, Md, MD
Hematology & Oncology — Payments: $291,732
Hematology & Oncology $291,732